Abstract:Stroke is the leading cause of death and disability in ageing individuals. Previous epidemiological investigations and basic studies have demonstrated that estrogen replacement therapy exerted neuroprotective effects against stroke in menopausal women and ovariectomised (OVX) animals. The underlying mechanism remains unclear. ndrg2 is a new gene cloned in 2001 related to cell proliferation and differentiation, and stress responses. Our previous studies found that ndrg2 is specifically expressed in astrocytes in the brain and played an important role in cerebral ischaemic injury. However, the role of ndrg2 in estrogen neuroprotection against cerebral ischaemia has not been reported. In in vivo experiments, adult female C57 mice and ndrg2 gene knockout (ndrg2–/–) female mice were OVX and 7 days later treated with 50 μg kg–1 17β-estradiol (E2), 100 μg kg–1 E2, 2 mg kg–1 ERα agonist (PPT), or 8 mg kg–1 ERβ agonist (DPN) for 14 days. We detected the expression of ndrg2 mRNA and protein in brain tissue using real-time polymerase chain reaction (PCR), western blot, and immunofluorescence double labelling. We constructed a middle cerebral artery occlusion (MCAO) ischaemia model, and we also measured the expression of ndrg2 mRNA and protein at different times after reperfusion in the ischaemic penumbra. Triphenyltetrazolium chloride (TTC) staining was used to determine the ischaemic injury. In in vitro experiments, primary cultured astrocytes received E2, DPN, and PPT treatment. Real-time PCR and western blot were used to detect the expression of astrocyte ndrg2 mRNA and protein. We constructed an oxygen and glucose deprivation (OGD) model, and detected the expression of astrocyte ndrg2 mRNA and protein at different times after OGD. E2 or DPN treatment significantly up-regulated the expression of ndrg2 mRNA and protein in primary astrocytes and in the brain of OVX female. Expression of ndrg2 mRNA and protein in the ischaemic penumbra region after cerebral ischaemia was significantly increased 6 h after reperfusion and peaked at 24 h with nuclear translocation. Expression of ndrg2 mRNA and protein in primary astrocytes after OGD injury was significantly increased at 2 h after reoxygenation and peaked at 6 h also with nuclear translocation. ndrg2–/– female mice exhibited significantly larger infarct volume than ndrg2+/+ female mice. E2 or DPN replacement therapy significantly reduced infarct volume in ndrg2+/+-OVX female mice, but 50 μg kg–1 E2 or 8 mg kg– DPN replacement therapy did not significantly reduce infarct volume in ndrg2–/–-OVX female mice. Our study found that astrocyte ndrg2 is a target gene for estrogen and ERβ, and that estrogen or DPN replacement treatment significantly reduced cerebral ischaemia injury in OVX mice. Astrocyte ndrg2 is the key molecule mediating the neuroprotective effects of estrogen and ERβ against cerebral ischaemia and provides a potential new molecular target for estrogen neuroprotection.

Ndrg2: a Novel Target for Estrogen Neuroprotection Against Cerebral Ischaemia

N-myc Downstream-Regulated Gene 2 (Ndrg2): A Critical Mediator of Estrogen-Induced Neuroprotection Against Cerebral Ischemic Injury

Estrogen replacement therapy-induced neuroprotection against brain ischemia-reperfusion injury involves the activation of astrocytes via estrogen receptor β

Estrogen Regulates the Expression of Ndrg2 in Astrocytes

The Loss of Estrogen Efficacy Against Cerebral Ischemia in Aged Postmenopausal Female Mice

Estrogen-receptor-mediated protection of cerebral endothelial cell viability and mitochondrial function after ischemic insult in vitro.

G-Protein-Coupled Receptor 30 Mediates Rapid Neuroprotective Effects of Estrogen Via Depression of NR2B-Containing NMDA Receptors

Neuroprotective Effect of Estrogen: Role of Nonsynaptic Nr2b-Containing Nmda Receptors

Molecular Mechanism of Estrogen-Mediated Neuroprotection in the Relief of Brain Ischemic Injury

17Β-Estradiol Protects the Retinal Nerve Cells Suppressing TLR2 Mediated Immune-Inflammation and Apoptosis from Oxidative Stress Insult Independent of PI3K

Genistein Attenuates Brain Damage Induced by Transient Cerebral Ischemia Through Up-Regulation of ERK Activity in Ovariectomized Mice.

Neuronal GPER Participates in Genistein-Mediated Neuroprotection in Ischemic Stroke by Inhibiting NLRP3 Inflammasome Activation in Ovariectomized Female Mice

Inhibition of miR-181a protects female mice from transient focal cerebral ischemia by targeting astrocyte estrogen receptor-α.

Gonadal Hormones E2 and P Mitigate Cerebral Ischemia-Induced Upregulation of the AIM2 and NLRC4 Inflammasomes in Rats

Neuroprotective Effects of Oestrogen Against Oxidative Toxicity Through Activation of G‐protein‐coupled Receptor 30 Receptor

Pretreatment with 17β-Estradiol Attenuates Cerebral Ischemia-Induced Blood-Brain Barrier Disruption in Aged Rats: Involvement of Antioxidant Signaling

The Novel Estrogenic Receptor GPR30 Alleviates Ischemic Injury by Inhibiting TLR4-mediated Microglial Inflammation

Estrogen's sex-specific effects on ischemic cell death and estrogen receptor mRNA expression in rat cortical organotypic explants

The Effects of Different Doses of Estradiol (E2) on Cerebral Ischemia in an in Vitro Model of Oxygen and Glucose Deprivation and Reperfusion and in a Rat Model of Middle Carotid Artery Occlusion.

Differential Modulation of Estrogen Receptors (ers) in Ischemic Brain Injury: a Role for ERalpha in Estradiol-Mediated Protection Against Delayed Cell Death.

Differential Modulation of Estrogen Receptors (ERs) in Ischemic Brain Injury: A Role for ERα in Estradiol-Mediated Protection against Delayed Cell Death